INVEX Therapeutics Ltd (AU:IXC) — Market Cap & Net Worth
Market Cap & Net Worth: INVEX Therapeutics Ltd (IXC)
INVEX Therapeutics Ltd (AU:IXC) has a market capitalization of $5.85 Million (AU$8.27 Million) as of August 5, 2026. Listed on the AU stock exchange, this Australia-based company holds position #28263 globally and #1469 in its home market, demonstrating a -8.33% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying INVEX Therapeutics Ltd's stock price AU$0.11 by its total outstanding shares 75153848 (75.15 Million). Review IXC current and long-term liabilities to assess the company's total debt and financial obligations.
INVEX Therapeutics Ltd Market Cap History: 2019 to 2026
INVEX Therapeutics Ltd's market capitalization history from 2019 to 2026. Data shows change from $45.73 Million to $5.85 Million (-27.51% CAGR).
INVEX Therapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how INVEX Therapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
27.86x
INVEX Therapeutics Ltd's market cap is 27.86 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $45.73 Million | $130.00 | -$232.00K | 351780.59x | N/A |
| 2020 | $38.02 Million | $165.70K | -$3.36 Million | 229.46x | N/A |
| 2021 | $37.49 Million | $158.79K | -$2.28 Million | 236.09x | N/A |
| 2022 | $28.98 Million | $182.25K | -$3.95 Million | 159.02x | N/A |
| 2023 | $4.31 Million | $459.08K | -$7.75 Million | 9.38x | N/A |
| 2024 | $3.51 Million | $1.21 Million | -$1.64 Million | 2.90x | N/A |
| 2025 | $6.38 Million | $229.08K | -$476.87K | 27.86x | N/A |
Competitor Companies of IXC by Market Capitalization
Companies near INVEX Therapeutics Ltd in the global market cap rankings as of August 5, 2026.
Key companies related to INVEX Therapeutics Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #427 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #544 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #569 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $478.71 |
| #427 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $760.66 |
| #544 | Argen-X | BR:ARGX | $49.55 Billion | €728.00 |
| #569 | UCB SA | BR:UCB | $47.34 Billion | €223.30 |
INVEX Therapeutics Ltd Historical Marketcap From 2019 to 2026
Between 2019 and today, INVEX Therapeutics Ltd's market cap moved from $45.73 Million to $ 5.85 Million, with a yearly change of -27.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$5.85 Million | -8.33% |
| 2025 | AU$6.38 Million | +81.82% |
| 2024 | AU$3.51 Million | -18.52% |
| 2023 | AU$4.31 Million | -85.14% |
| 2022 | AU$28.98 Million | -22.70% |
| 2021 | AU$37.49 Million | -1.40% |
| 2020 | AU$38.02 Million | -16.86% |
| 2019 | AU$45.73 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 5th, 2026 the market cap of INVEX Therapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.85 Million USD |
| MoneyControl | $5.85 Million USD |
| MarketWatch | $5.85 Million USD |
| marketcap.company | $5.85 Million USD |
| Reuters | $5.85 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About INVEX Therapeutics Ltd
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II… Read more